A: Path -G (1+15) is safe, effective in diabetic patients with renal impairment. Patients with mild to severe kidney disease can take Path -G (1+15), but they should start slowly and gradually increase the dose (3✔✔Trusted Source Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment
A: Path -G (1+15) may cause weight gain. Sulfonylureas drugs commonly used to treat diabetes are associated with weight gain. Path -G (1+15) should be used in combination with a healthy diet and regular exercise to help control weight gain (2✔✔Trusted Source Glimepiride
Medindia adheres to strict ethical publishing standards to provide accurate, relevant, and current health content. We source our material from reputable places such as peer-reviewed journals, academic institutions, research bodies, medical associations, and occasionally, non-profit organizations. We welcome and value audience feedback as a part of our commitment to health literacy and informed decision-making.
3. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment - (https://pubmed.ncbi.nlm.nih.gov/8960852/#:)
Search for Drugs/Medicines
Medindia updates the prices regularly, however, there may be slight discrepancies in the prices displayed. This can be due to the following reasons:Medindia updates the prices regularly, however, there may be slight discrepancies in the prices displayed. This can be due to the following reasons:
Difference in GST/local taxes
Change in price by the company
Updation of price information may not have happened at the right time
For the above reasons, Medindia cannot be held liable for any action taken based on the information provided by its website. The purpose of this website is to provide initial guidance only and it does not intend to replace professional medical opinion in any manner whatsoever. Please also be aware that Medindia does not buy or sell medication.
Post a Comment
Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.